# Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer

> **NCT02644252** · PHASE3 · TERMINATED · sponsor: **Vejle Hospital** · enrollment: 79 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Day 1: Cisplatin 75 mg/m2
- **DRUG:** Day 1: Vinorelbine 25 mg/m2
- **DRUG:** Day 8: Capsule vinorelbine 50 mg/m2
- **DRUG:** Day 1: Carboplatin AUC=5
- **DRUG:** Day 1: Vinorelbine 30 mg/m2
- **DRUG:** Day 8: Capsule vinorelbine 60 mg/m2
- **DIETARY_SUPPLEMENT:** Tocotrienol 300 mg x 3 daily until progression
- **DRUG:** Placebo 1 capsule x 3 daily until progression

## Key facts

- **NCT ID:** NCT02644252
- **Lead sponsor:** Vejle Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01
- **Primary completion:** 2019-05-09
- **Final completion:** 2021-01-15
- **Target enrollment:** 79 (ACTUAL)
- **Why stopped:** The trial was ended prematurely because of a poor accrual rate
- **Last updated:** 2021-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02644252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02644252, "Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02644252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*